Zai Lab

Shanghai, China Founded: 2013 • Age: 13 yrs
Antibody-based therapies for cancers and inflammatory diseases are developed.
Request Access

About Zai Lab

Zai Lab is a company based in Shanghai (China) founded in 2013.. Zai Lab has raised $160 million across 3 funding rounds from investors including Kleiner Perkins, Orbimed and Qiming Venture Partners. The company has 1,870 employees as of December 31, 2024. Zai Lab offers products and services including Transformative Medicines and Innovative Therapies. Zai Lab operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.

  • Headquarter Shanghai, China
  • Employees 1870 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Zai Lab Ltd.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $400.44 M (USD)
    49.09
    as on Dec 31, 2024
  • Net Profit
    $-258.8 M (USD)
    23.42
    as on Dec 31, 2024
  • EBITDA
    $-262.67 M (USD)
    27.27
    as on Dec 31, 2024
  • Total Equity Funding
    $160 M (USD)

    in 3 rounds

  • Latest Funding Round
    $30 M (USD), Series C

    Jun 30, 2017

  • Investors
  • Employee Count
    1870

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Zai Lab

Zai Lab is a publicly listed company on the HKEX with ticker symbol 9688 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: HKEX · Ticker: 9688 . Sector: Health technology · Hong Kong

Products & Services of Zai Lab

Zai Lab offers a comprehensive portfolio of products and services, including Transformative Medicines and Innovative Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Develops treatments for oncology and infectious diseases through research.

Focuses on immunology and neuroscience solutions via clinical pipelines.

People of Zai Lab
Headcount 200-500
Employee Profiles 79
Board Members and Advisors 9
Employee Profiles
People
Samantha Du
Founder, Chairwoman & CEO
People
Justin Pham
IT Operations Manager
People
Erum Zaidi
HR Associate
People
Yajing Chen
CFO

Unlock access to complete

Board Members and Advisors
people
Peter Wirth
Director
people
William Lis
Director
people
John D. Diekman
Director
people
Nisa Leung
Director

Unlock access to complete

Funding Insights of Zai Lab

Zai Lab has successfully raised a total of $160M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series C — $30.0M
  • First Round

    (27 Aug 2014)

  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2017 Amount Series C - Zai Lab Valuation

investors

Jan, 2016 Amount Series B - Zai Lab Valuation

investors

Aug, 2014 Amount Series A - Zai Lab Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Zai Lab

Zai Lab has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Orbimed and Qiming Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
Venture capital and private equity firm
Founded Year Domain Location
Early-stage and late-stage biotech and finance companies are funded.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Zai Lab

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Zai Lab

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Zai Lab Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Zai Lab

Zai Lab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Zai Lab

When was Zai Lab founded?

Zai Lab was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Zai Lab located?

Zai Lab is headquartered in Shanghai, China.

Is Zai Lab a funded company?

Zai Lab is a funded company, having raised a total of $160M across 3 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Aug 27, 2014.

How many employees does Zai Lab have?

As of Dec 31, 2024, the latest employee count at Zai Lab is 1,870.

What is the annual revenue of Zai Lab?

Annual revenue of Zai Lab is $400.44M as on Dec 31, 2024.

What does Zai Lab do?

Zai Lab was founded in 2013 in Shanghai, China, within the biotechnology sector. Innovative drugs targeting anti-cancer and anti-inflammatory conditions are developed, including antibody-based therapies for hepatocellular carcinoma and lung cancer. Additional products address asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, and graft versus host disease. Operations center on research and development of these therapeutic solutions in the pharmaceutical industry.

Who are the top competitors of Zai Lab?

Zai Lab's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does Zai Lab offer?

Zai Lab offers Transformative Medicines and Innovative Therapies.

Is Zai Lab publicly traded?

Yes, Zai Lab is publicly traded on HKEX under the ticker symbol 9688.

Who are Zai Lab's investors?

Zai Lab has 9 investors. Key investors include Kleiner Perkins, Orbimed, Qiming Venture Partners, Vivo Capital, and Rock Springs Capital.

What is Zai Lab's ticker symbol?

The ticker symbol of Zai Lab is 9688 on HKEX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available